Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2010-022785-27-ES
EUCTR2010-022785-27-ESActive, not recruitingPhase 1

ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO DE BÚSQUEDA DE DOSIS EN FASE III PARA EVALUAR LA EFICACIA, DURACIÓN DE LA RESPUESTA Y SEGURIDAD DE XOLAIR (OMALIZUMAB) EN PACIENTES CON URTICARIA IDIOPÁTICA CRÓNICA (UIC) QUE PERMANECENSINTOMÁTICOS A PESAR DEL TRATAMIENTO CON ANTIHISTAMÍNICOS (H1) A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, RESPONSE DURATION AND SAFETY OF XOLAIR® (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE ANTIHISTAMINE TREATMENT (H1) - ASTERIA II

Genentech, Inc.0 sites322 target enrollmentStarted: November 18, 2011Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
322
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients must meet the following criteria for study entry:
  • •1. Aged 12?75 years (age limits may vary dependent upon regional restrictions).
  • •2. Diagnosis of CIU refractory to H1 antihistamines at the time of randomization,
  • •as defined by all of the following:
  • •The presence of itch and hives for ? 8 consecutive weeks at any time prior
  • •to enrollment despite current use of H1 antihistamine treatment during this
  • •time period UAS7 score (range 0?42) ? 16 and itch component of UAS7 (range 0?21)
  • •? 8 during 7 days prior to randomization (Week 0) In-clinic UAS ? 4 on at least one of the screening visit days (Day ?14, Day ? 7 or Day 1) Patients must have been on an approved dose of an H1 antihistamine for CIU for at least the 3 consecutive days immediately prior to the Day ?14 screening visit and must document current use on the day of the initial screening visit. CIU diagnosis for ? 6 months.
  • •3. Willing to give written informed consent, adhere to the visit schedules and meet
  • •study requirements.For those patients below the legal age of consent, the child must be willingto give written informed assent and the parent(s)/guardian(s) must be willing to give written informed consent. For patients below the legal age of consent, both child and parent must be able to adhere to dose and visit schedules and meet study requirements.
  • •4. Willing and able to complete a daily symptom eDiary for the duration of the
  • •5. Patients must not have any missing eDiary entries in the 7 days prior to
  • •randomization.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 1
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 10
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 2

Exclusion Criteria

  • •Patients who meet any of the following criteria will be excluded from study entry:
  • •1. Treatment with an investigational agent within 30 days of Day ?14.
  • •2. Weight less than 20 kg (44 lbs).
  • •3. Clearly defined underlying etiology for chronic urticarias other than CIU (main
  • •manifestation being physical urticaria). This includes the following urticarias:
  • •Acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact
  • •As well as the following diseases as these diseases may have symptoms
  • •of urticaria or angioedema Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia,
  • •or generalized cancer.
  • •4. Evidence of parasitic infection defined as having the following three items:
  • •Risk factors for parasitic disease (living in an endemic area, chronic GI symptoms, travel within the last 6 months to an endemic area and/or chronic immunosuppression)
  • •An absolute eosinophil count more than twice the upper limit of normal
  • •Evidence of parasitic colonization or infection on stool evaluation for ova and
  • •parasites. Note that stool ova and parasite evaluation will only be conducted
  • •in patients with both risk factors and an eosinophil count more than twice the
  • •upper limit of normal.
  • •5. Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus
  • •or other skin disease associated with itch.
  • •6. Previous treatment with omalizumab within a year prior to Day ?14.
  • •7. Routine (daily or every other day during 5 or more consecutive days) doses of
  • •the following medications within 30 days prior to Day ?14: systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.
  • •8. IV immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to Day ?14.
  • •9. Regular (daily/every other day) doxepin (oral) use within 14 days prior to
  • •10. Any H2 antihistamine use within 7 days prior to Day ?14.
  • •11. Any LTRA (montelukast or zafirlukast) within 7 days prior to Day ?14.
  • •12. Any H1 antihistamines at greater than approved doses within 3 days prior to
  • •13. Patients with current malignancy, history of malignancy, or currently under
  • •work-up for suspected malignancy except non-melanoma skin cancer that has
  • •been treated or excised and is considered resolved.
  • •14 .Hypersensitivity to omalizumab or any component of the formulation.
  • •15. History of anaphylactic shock.
  • •16. Presence of clinically significant cardiovascular, neurological, psychiatric,
  • •metabolic or other pathological conditions that could interfere with the
  • •interpretation of the study results and or compromise the safety of the patients.
  • •17. Medical examination or laboratory findings that suggest the possibility of
  • •decompensation of co-existing conditions for the duration of the study.
  • •Any items that are cause for uncertainty must be reviewed with the Medical Monitor.
  • •18. Inability to comply with study and follow-up procedures.
  • •19. Evidence of current drug or alcohol abuse.
  • •20. Nursing women or women of childbearing potential, defined as all women
  • •physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontan

Investigators

Similar Trials

Active, not recruiting
Phase 1
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO, EN FASE 3 DE LA EFICACIA Y SEGURIDAD DE SUNITINIB (SU011248) EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO AVANZADO / METASTÁSICO TRATADOS CON ERLOTINIBA MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTASIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIBCáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico tras el fracaso de al menos una pauta de quimioterapia previa.Locally advanced or metastasic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimenMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastatic
EUCTR2007-001915-52-ESPfizer, S.A.956
Active, not recruiting
Not Applicable
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE JNJ-42160443 EN PACIENTES CON NEURALGIA POSTHERPÉTICA Y NEURALGIA POSTRAUMÁTICA, SEGUIDO DE UN PERIODO DE EXTENSIÓN DOBLE CIEGO DE SEGURIDAD Y UNA EXTENSIÓN ABIERTA DE SEGURIDAD.
EUCTR2008-007478-39-ESJanssen Cilag International, N.V.200
Active, not recruiting
Phase 1
ESTUDIO MULTICÉNTRICO, ALEATORIZADO Y DOBLE CIEGO, COMPARATIVO DE LA SEGURIDAD Y EFICACIA DE UNA DOSIS AL DÍA DE TIGECICLINA FRENTE A ERTAPENEM EN EL TRATAMIENTO DE LAS INFECCIONES DEL PIE DEL PACIENTE DIABÉTICOA Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with DiabetesInfecciones del pie del paciente diabéticoSubjects with diabetes with a qualifying foot infection.
EUCTR2006-002257-76-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.1,065
Active, not recruiting
Phase 1
ESTUDIO ALEATORIZADO, DOBLE CIEGO, MULTICÉNTRICO, DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PREGABALINA EN COMPARACIÓN CON PLACEBO COMO TRATAMIENTO COMPLEMENTARIO DEL DOLOR POSTOPERATORIO TRAS LA REPARACIÓN DE UNA HERNIA INGUINAL PRIMARIAA RANDOMIZED, DOUBLE BLIND MULTI CENTER DOSE RANGING STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE ADJUNCTIVE TREATMENT OF POST SURGICAL PAIN AFTER PRIMARY INGUINAL HERNIA REPAIR - N/ADOLOR POSTOPERATORIOPOST SURGICAL PAINMedDRA version: 9.1Level: LLTClassification code 10036236Term: Postoperative pain relief
EUCTR2007-003656-11-ESPfizer, S.A400
Active, not recruiting
Phase 1
ESTUDIO ALEATORIZADO, DOBLE CIEGO, MULTICÉNTRICO, DE DOSIS RESPUESTA, CON GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PF 00885706, UN AGONISTA PARCIAL DEL RECEPTOR 5 HT4, EN TERAPIA AÑADIDA A ESOMEPRAZOL, PARA EL ALIVIO DE LOS SÍNTOMAS EN PACIENTES CON ENFERMEDAD POR REFLUJO GASTROESOFÁGICO (ERGE) CON POCA RESPUESTA A LOS INHIBIDORES DE LA BOMBA DE PROTONESA PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FOR THE RELIEF OF SYMPTOMS IN SUBJECTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) WHO HAVE A POOR RESPONSE TO PROTON PUMP INHIBITOR (PPI) TREATMENTEnfermedad por Reflujo Gastroesofágico (ERGE)GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)MedDRA version: 9.1Level: LLTClassification code 10018203Term: GERD
EUCTR2007-001487-67-ESPfizer, S.A.450